Bluebird Spinoff 2seventy Bio Gets Its Own Wings
Executive Summary
The formal split between the companies had been in the works since January, with 2seventy set to take over oncology operations while bluebird focuses on gene therapies.
You may also be interested in...
Finance Watch: Evotec, LianBio, IO Biotech Launch IPOs, Bringing US Total To 101
Public Company Edition: Blade will merge with a special purpose acquisition corporation to go public, Bluebird spins out 2seventy with $442m in cash and Compass raises $125m in a move to the Nasdaq.
Quick Listen: Scrip’s Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: a slow start for Biogen’s Aduhelm; J&J looks to transition COVID vaccine to commercial sales; 2seventy bio spins out from bluebird bio; UCB faces bimekizumab delays; and progress and setbacks in gene therapy.
As Cilta-Cel’s Big Day Approaches, Legend Looks Beyond Myeloma
CEO Ying Huang talked about the biotech’s plans for CAR-T therapies after its J&J-partnered program.